drugset / Trial / NCT04189848

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

NCT04189848

Phase 4 Completed 104 enrolled Novo Nordisk A/S
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin). Participants will receive 1 dose of semaglutide 0.25 mg and 1 dose of dulaglutide 0.75 mg on the same day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Timeline

Start
2019-12-03
Primary completion
2020-01-29
Completion
2020-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous
Subject Semaglutide Peptide 0.25 mg Subcutaneous